These results support neuroinflammation and astrogliosis as relevant contributors to Alzheimer's disease pathogenesis, which can be monitored through blood sampling, and suggest neuroinflammation as a potential target for future disease-modifying therapeutic trials targeting tau pathology. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.